4th Quarter - Report

VIR BIOTECHNOLOGY, INC. for VIR BIOTECHNOLOGY, INC.

Firm
Client
Income
—
Expenses
$120,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Reimbursement of COVID-19 Therapeutics

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Office of Science & Technology Policy (OSTP)

Science/Technology SCI

Pandemic Preparedness

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

S. 2640, Disease X Act; S. 3258/H.R 6025, Flu Vaccine Act; Build Back Better - Prescription Drug Policy, Pandemic Preparedness Funding; COVID-19 Response and COVID-19 Therapeutics Procurements; Pandemic Preparedness.

LobbyistCovered position, as disclosed
DOUGLAS STOSS —

Contacted: Office of Science & Technology Policy (OSTP); Centers For Medicare and Medicaid Services (CMS); Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 2640 (117th), H.R. 6025 (117th), S. 3258 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.